Esen KIYAN, Yasemin YALÇINKAYA, Ahmet GÜL, Murat İNANÇ, Mahmude Lale ÖÇAL, Bahar ARTIM ESEN, Ali Aslan DEMİR, Naci ŞENKAL

Interstitial lung disease in patients with systemic lupus erythematosus: a cohort study

Background/aim: Systemic lupus erythematosus (SLE) is an autoimmune disease with a variety of organ/system involvement. Respiratory system involvement is common in these patients and usually manifests itself by disorders of the lung parenchyma, pleura, pulmonary vasculature or diaphragm. In this study, we sought to determine the frequency of interstitial lung disease (ILD) in patients with SLE and associated risk factors. Materials and methods: Three hundred randomly chosen patients with SLE were included. Chest x-ray (CXR), lung spirometry and carbon monoxide diffusion test (DLCO) were performed. High-resolution thorax computed tomography (HRCT) was performed for a definite diagnosis of ILD. Results: Of 300 patients, 16% had ILD. At the start of the study, the prevalence obtained from the patients’ records showed that 4% had ILD. The median age, mean duration of disease, and follow-up time were significantly higher and longer in patients with ILD compared to patients without (p < 0.05). Forced expiratory volume (FEV1), forced vital capacity (FVC), DLCO and total lung capacity (TLC) were significantly lower in patients with ILD (p < 0.001). Patients with ILD had a significantly higher frequency of arthritis, serositis, Raynaud’s phenomenon, myositis, and anti-Scl70 positivity (p = 0.01, 0.001, 0.02, 0.004, and 0.001, respectively). A significantly higher number of patients had stopped using hydroxychloroquine (HCQ) in the ILD group (p = 0.04). Conclusion: ILD is common in patients with SLE. Spirometry, diffusion tests, and CXR are simple but valuable tools to diagnose ILD in patients with SLE. Considering the significant difference of prevalence between the start and the end of the study, one of the possibilities is the underrecognition of SLE-associated interstitial pulmonary disease. The higher administration of immunosuppressives in these patients may support a multisystemic active disease including the lungs

PDF

___

1. Ugarte-Gil MF, Alarcon GS. History of systemic lupus erythematosus. In: Gordon C, Isenberg D, eds. Systemic Lupus Erythematosus. 1st ed. Oxford, UK: Oxford University Press; 2016:1-6.
2. Yoo H, Hino T, Han J, Franks TJ, Im Y et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. European Journal of Radiology Open. 2020 Dec 16;8:100311. doi: 10.1016/j. ejro.2020.100311
3. Tsokos G. Systemic Lupus Erythematosus Basic, Applied and Clinical Aspects. 1st ed. Elsevier; 2015.
4. Paul F. Dellaripa, Aryeh Fischer, Kevin R. Flaherty. Pulmonary Manifestations of Rheumatic Disease. Springer; 2014
5. Toyoda Y, Koyama K, Kawano H, Nishimura H, Kagawa K at al. Clinical features of interstitial pneumonia associated with systemic lupus erythematosus. Respiratory Investigation. 2019 Sep;57(5):435-443. doi: 10.1016/j.resinv.2019.04.005
6. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatology. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473
7. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco Vet al. Standardisation of the measurement of lung volumes. European Respiratory Journal 2005; 26: 511–22. doi: 10.1183/09031936.05.00035005
8. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP et al. Standardisation of the singlebreath determination of carbon monoxide uptake in the lung. European Respiratory Journal 2005;26:720–35. doi: 10.1183/09031936.05.00034905
9. Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R et al. 2017 ERS/ ATS standards for single-breath carbon monoxide uptake in the lung. European Respiratory Journal 2017;49. doi: 10.1183/13993003.00016-2016
10. Johnson D. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume. Respiratory Medicine 2000; 94: 28–37. doi: 10.1053/rmed.1999.0740
11. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F et al. Interpretative strategies for lung function tests. European Respiratory Journal 2005; 26: 948–68. doi: 10.1053/ rmed.1999.0740
12. Narvaez J, Borrell H, Sánchez-Alonso F, Rúa-Figueroa I, López-Longo FJ et al. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. Arthritis Research and Therapy. 2018;19;20(1):280. doi: 10.1186/s13075-018-1776-8
13. Haye Salinas MJ, Caeiro F, Saurit V, Alvarellos A, Wojdyla D et al. Pleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL). Lupus. 2017;26(13):1368-1377. doi: 10.1177/0961203317699284
14. Nakano M, Hasegawa H, Takada T, Ito S, Muramatsu Y et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology. 2002;7(1):45-9. doi: 10.1046/j.1440-1843.2002.00361.x
15. Enomoto N, Egashira R, Tabata K, Hashisako M, Kitani M et al. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Scientific Reports. 2019;14;9(1):7355. doi: 10.1038/s41598-019-43782-7
16. Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K et al. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2020. doi: 10.1111/1756-185X.13792
17. Hsu CY, Lin YS, Cheng TT, Syu YJ, Lin MS et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2018 Oct 1;57(10):1743-1751. doi: 10.1093/rheumatology/ key167